Pfizer signs agreement to allow broader access to its Covid-19 pill

Pfizer has signed a licensing agreement in order to allow broader global access towards its Covid-19 treatment pill.

The agreement  was made with the a UN-backed public health organization called “Medicines Patent Pool”. This will give allowance to generic manufacturers who will then make the pill widely available in 95 middle-income countries covering 53% of the world’s population, according to the company’s statement.

The pill is called PF-07321332 or Paxlovid, and it is to be given in combination with an older antiviral drug called ritonavir.

Pfizer announced topline results from its trial saying that an interim analysis , done before the trial was scheduled to end showed an 89% reduction in the risk of hospitalization or death from Covid-19 among people given the drug within the first three days of symptom onset.

According to Pfizer’s statement , the company will profit in the sales in low-income countries and will further waive royalties on sales in all countries covered by the agreement while COVID-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization.
Stay tuned to Baaghi TV for latest news and updates!
Facebook Notice for EU! You need to login to view and post FB Comments!